It seems likely they will secure patents on cagrisema that include much larger sema amounts than the usual amounts, drawing from work like the ones mentioned. Raising the levels of ordinary sema alone feels unlikely because the digestive troubles already hit so many users hard. The intended spot for cagrisema remains unclear to me, though it might go up against tirzepatide for those who see no weight drop from it. Only a tiny share of users fall into that category. Before long the supply of glp compounds will probably overflow the space. Does room really exist for sema, tirz, reta, maz, survo, cagrisema, orforglipron plus whatever else arrives, when tirz already meets the needs of nearly everyone?